NICE final guidance disappoints Novartis
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has published several sets of final and binding guidance on a range of drugs, including Novartis' Jakavi (ruxolitinib). The firm is unimpressed with the negative guidance and wants an early review.